HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Graduate School of Medicine / Faculty of Medicine >
Peer-reviewed Journal Articles, etc >

Phase I study of stereotactic body radiation therapy for peripheral T2N0M0 non-small cell lung cancer with PTV < 100 cc using a continual reassessment method (JCOG0702)

Creative Commons License

Files in This Item:
manuscript+appendix.pdf838.79 kBPDFView/Open
Please use this identifier to cite or link to this item:http://hdl.handle.net/2115/62578

Title: Phase I study of stereotactic body radiation therapy for peripheral T2N0M0 non-small cell lung cancer with PTV < 100 cc using a continual reassessment method (JCOG0702)
Authors: Onimaru, Rikiya Browse this author →KAKEN DB
Shirato, Hiroki Browse this author →KAKEN DB
Shibata, Taro Browse this author
Hiraoka, Masahiro Browse this author →KAKEN DB
Ishikura, Satoshi Browse this author
Karasawa, Katsuyuki Browse this author
Matsuo, Yukinori Browse this author →KAKEN DB
Kokubo, Masaki Browse this author →KAKEN DB
Shioyama, Yoshiyuki Browse this author →KAKEN DB
Matsushita, Haruo Browse this author →KAKEN DB
Ito, Yoshinori Browse this author
Onishi, Hiroshi Browse this author →KAKEN DB
Keywords: Phase I study
Continual reassessment method
Non-small cell lung cancer (NSCLC)
Stereotactic body radiotherapy
SBRT
Issue Date: Aug-2015
Publisher: Elsevier
Journal Title: Radiotherapy and oncology
Volume: 116
Issue: 2
Start Page: 276
End Page: 280
Publisher DOI: 10.1016/j.radonc.2015.07.008
PMID: 26233591
Abstract: Purpose: To estimate the maximum tolerated dose (MTD) and to determine the recommended dose (RD) of stereotactic body radiation therapy (SBRT) for peripheral T2N0M0 non-small cell carcinoma (NSCLC) with target volume (PTV) < 100 cc. Materials and methods: The continual reassessment method (CRM) was used to determine the dose level that patients should be assigned to and to estimate the MTD. Dose limiting toxicity (DLT) was grade 3 radiation pneumonitis (RP) within 180 days after the start of SBRT, grade 2 RP was used as a surrogate DLT. The RD was equal to the MTD. The dose was prescribed at D95 of the PTV. Results: Fifteen patients were accrued. Only 1 experienced grade 2 RP at 60 Gy in 4 fractions. It was difficult to fulfill the dose constraints at 60 Gy in 4 fractions, and the maximum dose level assigned by CRM was changed to 55 Gy in 4 fractions. The lower limit of 95% of the credible interval exceeded the adjacent level, and the RD was determined as 55 Gy in 4 fractions. Conclusions: The RD of SBRT for peripheral T2N0M0 NSCLC with PTV < 100 cc was determined to be 55 Gy in 4 fractions.
Rights: © 2015, Elsevier. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/
http://creativecommons.org/licenses/by-nc-nd/4.0/
Type: article (author version)
URI: http://hdl.handle.net/2115/62578
Appears in Collections:国際連携研究教育局 : GI-CoRE (Global Institution for Collaborative Research and Education : GI-CoRE) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Submitter: 鬼丸 力也

Export metadata:

OAI-PMH ( junii2 , jpcoar )

MathJax is now OFF:


 

Feedback - Hokkaido University